[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_b6a21e74-e434-4191-b01a-a4ca090e87a1]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]Charles Schwab Investment Management Inc. Increases Stock Position in AMN Healthcare Services Inc $AMN:
[TEXT]
Charles Schwab Investment Management Inc. boosted its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 1.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 904,275 shares of the company’s stock after purchasing an additional 17,064 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AMN Healthcare Services were worth $22,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC raised its stake in AMN Healthcare Services by 34.4% in the first quarter. Janney Montgomery Scott LLC now owns 15,145 shares of the company’s stock valued at $370,000 after purchasing an additional 3,880 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $592,000. Golden State Wealth Management LLC grew its position in AMN Healthcare Services by 107.0% during the first quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after acquiring an additional 599 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $1,581,000. Finally, GAMMA Investing LLC grew its position in AMN Healthcare Services by 74.9% during the first quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after acquiring an additional 2,260 shares during the last quarter. 99.23% of the stock is owned by hedge funds and other institutional investors.

Get AMN Healthcare Services alerts:

AMN Healthcare Services Stock Down 3.1%

Shares of AMN Healthcare Services stock opened at $19.6650 on Friday. The company has a debt-to-equity ratio of 1.51, a quick ratio of 1.00 and a current ratio of 1.00. AMN Healthcare Services Inc has a 52-week low of $14.86 and a 52-week high of $54.01. The stock has a market capitalization of $753.56 million, a price-to-earnings ratio of -2.53 and a beta of 0.10. The company’s 50 day moving average price is $20.07 and its 200-day moving average price is $21.65.

Wall Street Analyst Weigh In

AMN Healthcare Services ( NYSE:AMN Get Free Report ) last issued its earnings results on Thursday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.13. AMN Healthcare Services had a negative net margin of 10.75% and a positive return on equity of 11.09%. The firm had revenue of $658.18 million for the quarter, compared to analysts’ expectations of $652.89 million. During the same quarter last year, the business earned $0.98 earnings per share. The business’s revenue was down 11.1% on a year-over-year basis. AMN Healthcare Services has set its Q3 2025 guidance at EPS. Equities research analysts forecast that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

A number of brokerages have commented on AMN. UBS Group reduced their price target on shares of AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. BMO Capital Markets reduced their price target on shares of AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, August 11th. Finally, JMP Securities reduced their price target on shares of AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AMN Healthcare Services currently has an average rating of “Hold” and a consensus price target of $28.25.

Get Our Latest Report on AMN
[Source link]: https://www.etfdailynews.com/2025/08/22/charles-schwab-investment-management-inc-increases-stock-position-in-amn-healthcare-services-inc-amn/

================================================================================

[TITLE]Charles Schwab Investment Management Inc. Increases Stock Position in AMN Healthcare Services Inc $AMN:
[TEXT]
Charles Schwab Investment Management Inc. boosted its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 1.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 904,275 shares of the company’s stock after purchasing an additional 17,064 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AMN Healthcare Services were worth $22,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC raised its stake in AMN Healthcare Services by 34.4% in the first quarter. Janney Montgomery Scott LLC now owns 15,145 shares of the company’s stock valued at $370,000 after purchasing an additional 3,880 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $592,000. Golden State Wealth Management LLC grew its position in AMN Healthcare Services by 107.0% during the first quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after acquiring an additional 599 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in AMN Healthcare Services during the first quarter valued at approximately $1,581,000. Finally, GAMMA Investing LLC grew its position in AMN Healthcare Services by 74.9% during the first quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after acquiring an additional 2,260 shares during the last quarter. 99.23% of the stock is owned by hedge funds and other institutional investors.

Get AMN Healthcare Services alerts:

AMN Healthcare Services Stock Down 3.1%

Shares of AMN Healthcare Services stock opened at $19.6650 on Friday. The company has a debt-to-equity ratio of 1.51, a quick ratio of 1.00 and a current ratio of 1.00. AMN Healthcare Services Inc has a 52-week low of $14.86 and a 52-week high of $54.01. The stock has a market capitalization of $753.56 million, a price-to-earnings ratio of -2.53 and a beta of 0.10. The company’s 50 day moving average price is $20.07 and its 200-day moving average price is $21.65.

Wall Street Analyst Weigh In

AMN Healthcare Services ( NYSE:AMN Get Free Report ) last issued its earnings results on Thursday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.13. AMN Healthcare Services had a negative net margin of 10.75% and a positive return on equity of 11.09%. The firm had revenue of $658.18 million for the quarter, compared to analysts’ expectations of $652.89 million. During the same quarter last year, the business earned $0.98 earnings per share. The business’s revenue was down 11.1% on a year-over-year basis. AMN Healthcare Services has set its Q3 2025 guidance at EPS. Equities research analysts forecast that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

A number of brokerages have commented on AMN. UBS Group reduced their price target on shares of AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. BMO Capital Markets reduced their price target on shares of AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, August 11th. Finally, JMP Securities reduced their price target on shares of AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AMN Healthcare Services currently has an average rating of “Hold” and a consensus price target of $28.25.

Get Our Latest Report on AMN
[Source link]: https://www.etfdailynews.com/2025/08/22/charles-schwab-investment-management-inc-increases-stock-position-in-amn-healthcare-services-inc-amn/


[TITLE]Public Sector Pension Investment Board Has $2.35 Million Stock Position in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Public Sector Pension Investment Board grew its holdings in shares of Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) by 27.6% in the first quarter, Holdings Channel reports. The institutional investor owned 233,034 shares of the business services provider’s stock after acquiring an additional 50,462 shares during the period. Public Sector Pension Investment Board’s holdings in Healthcare Services Group were worth $2,349,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Sterling Capital Management LLC grew its holdings in shares of Healthcare Services Group by 803.4% during the fourth quarter. Sterling Capital Management LLC now owns 2,358 shares of the business services provider’s stock valued at $27,000 after buying an additional 2,097 shares during the last quarter. US Bancorp DE grew its holdings in shares of Healthcare Services Group by 161.4% during the first quarter. US Bancorp DE now owns 8,097 shares of the business services provider’s stock valued at $82,000 after buying an additional 5,000 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Healthcare Services Group during the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/20/public-sector-pension-investment-board-has-2-35-million-stock-position-in-healthcare-services-group-inc-hcsg/


[TITLE]Molina Healthcare, Inc $MOH Shares Acquired by Public Sector Pension Investment Board:
[TEXT]
Public Sector Pension Investment Board raised its position in Molina Healthcare, Inc (NYSE:MOH – Free Report) by 5.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,421 shares of the company’s stock after buying an additional 406 shares during the period. Public Sector Pension Investment Board’s holdings in Molina Healthcare were worth $2,444,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MOH. GAMMA Investing LLC increased its holdings in Molina Healthcare by 74,593.7% in the first quarter. GAMMA Investing LLC now owns 667,015 shares of the company’s stock valued at $219,708,000 after buying an additional 666,122 shares in the last quarter. Voloridge Investment Management LLC raised its stake in shares of Molina Healthcare by 1,641.3% during the 4th quarter. Voloridge Investment Management LLC now owns 409,807 shares of the company’s stock worth $119,274,000 after buying an additional 386,273 shares during the period. Two Sigma Investments LP acquired a new position in shares of Molina Healthcare during the 4th quarter worth approximately $44,099,000. Nuveen LLC acquired a new position in shares of Molina Healthcare during the 1st quarter worth approximately $46,441,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Molina Healthcare by 138.4% during the 4th quarter. BNP Paribas Financial Markets now owns 177,150 shares of the company’s stock worth $51,560,000 after buying an additional 102,840 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Get Molina Healthcare alerts:

Molina Healthcare Stock Up 2.7%

Shares of MOH opened at $173.64 on Wednesday. Molina Healthcare, Inc has a 52-week low of $151.95 and a 52-week high of $365.23. The company has a market capitalization of $9.41 billion, a PE ratio of 8.56 and a beta of 0.52. The stock has a fifty day simple moving average of $218.31 and a two-hundred day simple moving average of $279.84. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.77.

Analyst Ratings Changes

Molina Healthcare ( NYSE:MOH Get Free Report ) last issued its earnings results on Wednesday, July 23rd. The company reported $5.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.50 by ($0.02). The company had revenue of $11.43 billion during the quarter, compared to analyst estimates of $10.94 billion. Molina Healthcare had a return on equity of 27.72% and a net margin of 2.60%.The firm’s revenue was up 15.7% compared to the same quarter last year. During the same period last year, the business earned $5.86 earnings per share. As a group, equities analysts forecast that Molina Healthcare, Inc will post 24.4 EPS for the current year.

Several brokerages have recently weighed in on MOH. Morgan Stanley downgraded Molina Healthcare from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $364.00 to $266.00 in a research note on Thursday, July 10th. Cantor Fitzgerald reissued a “neutral” rating and issued a $210.00 price objective (down from $312.00) on shares of Molina Healthcare in a research note on Friday, July 25th. Truist Financial reissued a “hold” rating and issued a $180.00 price objective (down from $335.00) on shares of Molina Healthcare in a research note on Friday, July 25th. Barclays reduced their price objective on Molina Healthcare from $270.00 to $186.00 and set an “equal weight” rating for the company in a research note on Friday, July 25th. Finally, Sanford C. Bernstein began coverage on Molina Healthcare in a research note on Tuesday, April 22nd. They issued an “outperform” rating and a $414.00 price objective for the company. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $242.91.

Read Our Latest Research Report on MOH

Insider Transactions at Molina Healthcare

In related news, Director Ronna Romney sold 700 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $153.74, for a total transaction of $107,618.00. Following the completion of the transaction, the director directly owned 17,131 shares in the company, valued at $2,633,719.94. This trade represents a 3.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO James Woys purchased 10,000 shares of Molina Healthcare stock in a transaction on Monday, August 4th. The stock was bought at an average cost of $155.94 per share, for a total transaction of $1,559,400.00. Following the transaction, the chief operating officer directly owned 74,331 shares in the company, valued at $11,591,176.14. This represents a 15.54% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.26% of the company’s stock.

Molina Healthcare Company Profile

(Free Report)

Molina Healthcare, Inc provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.

Read More

Want to see what other hedge funds are holding MOH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Molina Healthcare, Inc (NYSE:MOH – Free Report).

Receive News & Ratings for Molina Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molina Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/20/molina-healthcare-inc-moh-shares-acquired-by-public-sector-pension-investment-board/


[TITLE]Connor Clark & Lunn Investment Management Ltd. Purchases 103,529 Shares of Definitive Healthcare Corp. $DH:
[TEXT]
Connor Clark & Lunn Investment Management Ltd. increased its position in Definitive Healthcare Corp. (NASDAQ:DH – Free Report) by 70.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 250,152 shares of the company’s stock after purchasing an additional 103,529 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Definitive Healthcare were worth $723,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its stake in Definitive Healthcare by 9.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 458,936 shares of the company’s stock valued at $1,326,000 after buying an additional 38,443 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Definitive Healthcare in the 1st quarter valued at about $76,000. Pinnacle Wealth Management Advisory Group LLC acquired a new position in Definitive Healthcare in the 1st quarter valued at about $751,000. Pinnacle Associates Ltd. acquired a new position in Definitive Healthcare in the 1st quarter valued at about $751,000. Finally, Allianz Asset Management GmbH grew its stake in Definitive Healthcare by 70.0% in the 1st quarter. Allianz Asset Management GmbH now owns 42,000 shares of the company’s stock valued at $121,000 after buying an additional 17,300 shares during the last quarter. 98.67% of the stock is owned by institutional investors.

Get Definitive Healthcare alerts:

Definitive Healthcare Stock Up 1.6%

DH stock opened at $3.93 on Tuesday. The company has a market cap of $562.54 million, a PE ratio of -1.48, a price-to-earnings-growth ratio of 6.51 and a beta of 1.64. The business has a 50-day simple moving average of $3.92 and a 200 day simple moving average of $3.56. Definitive Healthcare Corp. has a 52 week low of $2.15 and a 52 week high of $5.68. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.39.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Robert W. Baird set a $4.00 price target on shares of Definitive Healthcare in a research note on Friday, August 8th. Stifel Nicolaus upped their price target on shares of Definitive Healthcare from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, June 21st. BTIG Research cut shares of Definitive Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 9th. Finally, The Goldman Sachs Group raised their target price on shares of Definitive Healthcare from $3.00 to $3.40 and gave the stock a “neutral” rating in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.73.

Get Our Latest Research Report on Definitive Healthcare

About Definitive Healthcare

(Free Report)

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.

See Also

Want to see what other hedge funds are holding DH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definitive Healthcare Corp. (NASDAQ:DH – Free Report).

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/19/connor-clark-lunn-investment-management-ltd-purchases-103529-shares-of-definitive-healthcare-corp-dh/

================================================================================

[TITLE]Invesco Ltd. Has $17.38 Million Stake in Supernus Pharmaceuticals, Inc. $SUPN:
[TEXT]
Invesco Ltd. boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 530,631 shares of the specialty pharmaceutical company’s stock after buying an additional 22,562 shares during the quarter. Invesco Ltd.’s holdings in Supernus Pharmaceuticals were worth $17,378,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Raiffeisen Bank International AG acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth $25,000. Financial Management Professionals Inc. acquired a new position in Supernus Pharmaceuticals during the first quarter worth $30,000. Versant Capital Management Inc increased its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/22/invesco-ltd-has-17-38-million-stake-in-supernus-pharmaceuticals-inc-supn/


[TITLE]Amneal Pharmaceuticals, Inc. $AMRX Stake Lifted by Vanguard Group Inc.:
[TEXT]
Vanguard Group Inc. lifted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,762,727 shares of the company’s stock after purchasing an additional 920,758 shares during the quarter. Vanguard Group Inc. owned 0.05% of Amneal Pharmaceuticals worth $132,092,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Janney Montgomery Scott LLC grew its stake in shares of Amneal Pharmaceuticals by 26.9% in the first quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company’s stock worth $162,000 after purchasing an additional 4,100 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Amneal Pharmaceuticals by 53.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company’s stock worth $508,000 after purchasing an additional 21,079 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Amneal Pharmaceuticals by 45.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company’s stock worth $2,522,000 after purchasing an additional 99,866 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Amneal Pharmaceuticals by 10.3% in the fourth quarter. California State Teachers Retirement System now owns 131,713 shares of the company’s stock worth $1,043,000 after purchasing an additional 12,282 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Amneal Pharmaceuticals by 209.2% in the fourth quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company’s stock worth $1,332,000 after purchasing an additional 113,796 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Get Amneal Pharmaceuticals alerts:

Insider Activity

In other news, EVP Andrew S. Boyer sold 33,436 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $302,595.80. Following the completion of the sale, the executive vice president directly owned 256,670 shares of the company’s stock, valued at $2,322,863.50. This represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares of the company’s stock, valued at approximately $95,984.30. This represents a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 177,130 shares of company stock worth $1,619,733 over the last 90 days. 26.56% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AMRX has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a “buy” rating and a $12.00 price target for the company. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $11.60.

Read Our Latest Stock Report on AMRX

Amneal Pharmaceuticals Stock Up 1.3%

Shares of Amneal Pharmaceuticals stock opened at $9.53 on Friday. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of 953.95 and a beta of 1.11. The business has a fifty day simple moving average of $8.34 and a 200-day simple moving average of $8.00. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $9.62.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.
[Source link]: https://www.etfdailynews.com/2025/08/22/amneal-pharmaceuticals-inc-amrx-stake-lifted-by-vanguard-group-inc/


[TITLE]Vanguard Group Inc. Has $170.80 Million Stake in Recursion Pharmaceuticals, Inc. $RXRX:
[TEXT]
Vanguard Group Inc. trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 5.1% in the 1st quarter, Holdings Channel reports. The institutional investor owned 32,287,977 shares of the company’s stock after selling 1,722,017 shares during the period. Vanguard Group Inc. owned 0.08% of Recursion Pharmaceuticals worth $170,803,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after acquiring an additional 6,699 shares during the last quarter. Wells Fargo & Company MN grew its position in Recursion Pharmaceuticals by 298.5% during the fourth quarter. Wells Fargo & Company MN now owns 458,321 shares of the company’s stock worth $3,098,000 after buying an additional 343,304 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Recursion Pharmaceuticals by 5.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 231,756 shares of the company’s stock worth $1,567,000 after buying an additional 11,646 shares in the last quarter. Invesco Ltd. raised its position in Recursion Pharmaceuticals by 54.6% in the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company’s stock worth $1,207,000 after purchasing an additional 63,068 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Recursion Pharmaceuticals by 26.7% in the fourth quarter. Legal & General Group Plc now owns 253,426 shares of the company’s stock worth $1,713,000 after purchasing an additional 53,458 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Get Recursion Pharmaceuticals alerts:

Insiders Place Their Bets

In related news, insider Najat Khan sold 36,599 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.43% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Stock Down 6.3%

RXRX stock opened at $4.77 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The stock has a market capitalization of $2.07 billion, a P/E ratio of -2.68 and a beta of 0.93. The business has a 50-day moving average of $5.47 and a 200-day moving average of $5.80. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. Recursion Pharmaceuticals’s revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.00.

Get Our Latest Report on RXRX
[Source link]: https://www.etfdailynews.com/2025/08/21/vanguard-group-inc-has-170-80-million-stake-in-recursion-pharmaceuticals-inc-rxrx/


[TITLE]Nuveen LLC Buys New Stake in Crinetics Pharmaceuticals, Inc. $CRNX:
[TEXT]
Nuveen LLC bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 562,935 shares of the company’s stock, valued at approximately $18,881,000. Nuveen LLC owned 0.60% of Crinetics Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Crinetics Pharmaceuticals by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 9,311,600 shares of the company’s stock valued at $312,311,000 after acquiring an additional 222,209 shares during the period. Driehaus Capital Management LLC increased its position in Crinetics Pharmaceuticals by 4.3% in the 4th quarter. Driehaus Capital Management LLC now owns 6,141,014 shares of the company’s stock valued at $313,990,000 after acquiring an additional 255,766 shares during the period. Price T Rowe Associates Inc. MD increased its position in Crinetics Pharmaceuticals by 9.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,414,505 shares of the company’s stock valued at $276,844,000 after acquiring an additional 469,748 shares during the period. Farallon Capital Management LLC increased its position in Crinetics Pharmaceuticals by 250.7% in the 4th quarter. Farallon Capital Management LLC now owns 4,075,098 shares of the company’s stock valued at $208,360,000 after acquiring an additional 2,913,098 shares during the period. Finally, Janus Henderson Group PLC increased its position in Crinetics Pharmaceuticals by 15.1% in the 4th quarter. Janus Henderson Group PLC now owns 2,795,441 shares of the company’s stock valued at $142,902,000 after acquiring an additional 365,991 shares during the period. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Get Crinetics Pharmaceuticals alerts:

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on Crinetics Pharmaceuticals in a research report on Thursday, July 10th. They set a “neutral” rating and a $36.00 price target on the stock. JMP Securities lowered their price target on Crinetics Pharmaceuticals from $90.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Monday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $81.00 price target on shares of Crinetics Pharmaceuticals in a research report on Friday, June 27th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Crinetics Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $68.86.

Crinetics Pharmaceuticals Stock Down 1.0%

CRNX opened at $29.43 on Wednesday. The firm has a market cap of $2.77 billion, a PE ratio of -7.16 and a beta of 0.33. The business has a fifty day simple moving average of $30.16 and a 200-day simple moving average of $31.82. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $24.10 and a fifty-two week high of $62.53.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.10). The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.52 million. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.94) earnings per share. On average, equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, insider Stephen F. Betz sold 97,483 shares of the firm’s stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the completion of the sale, the insider directly owned 99,713 shares of the company’s stock, valued at $3,213,749.99. This trade represents a 49.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.00% of the stock is currently owned by corporate insiders.

Crinetics Pharmaceuticals Company Profile

(Free Report)

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

See Also

Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report).

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/20/nuveen-llc-buys-new-stake-in-crinetics-pharmaceuticals-inc-crnx/

================================================================================

[TITLE]Theratechnologies receives interim order in acquisition by CB Biotechnology THTX:
[TEXT]
Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4184845/THTX-Theratechnologies-receives-interim-order-in-acquisition-by-CB-Biotechnology


[Failed to load article at https://financialpost.com/globe-newswire/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-order-in-relation-to-its-acquisition-by-cb-biotechnology-an-affiliate-of-future-pak]


[TITLE]Theratechnologies Announces Filing of Special Meeting:
[TEXT]
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.

Board unanimously recommends shareholders vote “FOR” the Arrangement.

Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.

Visit www.theratech.com
[Source link]: https://www.globenewswire.com/news-release/2025/08/18/3134927/0/en/Theratechnologies-Announces-Filing-of-Special-Meeting-Materials-and-Receipt-of-Interim-Order-in-Relation-to-its-Acquisition-by-CB-Biotechnology-an-Affiliate-of-Future-Pak.html


[TITLE]Vir Biotechnology, Inc. $VIR Shares Acquired by Public Sector Pension Investment Board:
[TEXT]
Public Sector Pension Investment Board lifted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 27.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 292,578 shares of the company’s stock after purchasing an additional 63,284 shares during the period. Public Sector Pension Investment Board’s holdings in Vir Biotechnology were worth $1,896,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State of Tennessee Department of Treasury increased its position in shares of Vir Biotechnology by 3.2% during the fourth quarter. State of Tennessee Department of Treasury now owns 39,268 shares of the company’s stock worth $288,000 after purchasing an additional 1,227 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Vir Biotechnology by 26.2% during the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after purchasing an additional 2,171 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Vir Biotechnology by 0.6% during the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company’s stock worth $2,927,000 after buying an additional 2,574 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Vir Biotechnology by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,290 shares of the company’s stock worth $248,000 after buying an additional 3,209 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Vir Biotechnology by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 71,332 shares of the company’s stock worth $524,000 after buying an additional 3,506 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Get Vir Biotechnology alerts:

Wall Street Analyst Weigh In

A number of research firms recently issued reports on VIR. Raymond James Financial began coverage on Vir Biotechnology in a report on Friday, July 11th. They set an “outperform” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $14.00 price target on shares of Vir Biotechnology in a report on Thursday, May 22nd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.25.

Vir Biotechnology Stock Performance

Shares of VIR opened at $4.36 on Thursday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The stock’s 50 day moving average is $5.16 and its two-hundred day moving average is $6.14. The firm has a market capitalization of $605.69 million, a PE ratio of -1.09 and a beta of 1.18.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. During the same period in the prior year, the firm posted ($1.02) EPS. Vir Biotechnology’s revenue for the quarter was down 60.5% compared to the same quarter last year. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Insider Buying and Selling

In other Vir Biotechnology news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total value of $37,174.12. Following the sale, the executive vice president owned 108,204 shares of the company’s stock, valued at approximately $591,875.88. The trade was a 5.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $4.99, for a total value of $109,780.00. Following the sale, the director directly owned 1,276,391 shares in the company, valued at $6,369,191.09. This trade represents a 1.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,582 shares of company stock worth $294,930 in the last ninety days. 16.00% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

(Free Report)

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

Read More

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report).

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/21/vir-biotechnology-inc-vir-shares-acquired-by-public-sector-pension-investment-board/

================================================================================

[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_409e47c7-7649-4e68-bb06-624ee2b90d5f]


[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_b6a21e74-e434-4191-b01a-a4ca090e87a1]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]

================================================================================

